Meet with Bayer

Firialta was evaluated in >13,000 patients with early-to late-stage CKD1*

99.8% of patients were on the maximum tolerated dose of an ACEi or ARB, and 97.7% were on at least one glucose-lowering agent

FIGARO-DKD TRIAL
(CV-FOCUSED)2

Primary composite endpoint:

  • CV death
  • Non-fatal MI
  • Non-fatal stroke
  • HF hospitalisation

FIDELIO-DKD TRIAL
(RENAL-FOCUSED)3

Primary composite endpoint:

  • Kidney failure
  • Sustained decline of ≥40% in eGFR
  • Kidney death
     
Patient icon
Patient icon

Firialta was evaluated in a large phase 3 clinical trial program1

FIGARO-DKD TRIAL

CV mortality and morbidity
(N=7437†)2

FIDELIO-DKD TRIAL

Kidney failure and disease
progression
(N=5734†)3

FIDELITY

Prespecified pooled analysis
(N=13,171†)1

Study designs for FIGARO-DKD and FIDELIO-DKD1,4,5

Alt tag

Patient characteristics were well-balanced between groups in both trials2,3

 
FIGARO-DKD
FIDELIO-DKD
Baseline Characteristics
Firialta
(n=3686)
Placebo
(n=3666)
Firialta
(n=2833)
Placebo
(n=2841)
Mean eGFR (mL/min/1.73 m2)
67.6
68.0
44.4
44.3
eGFR <45 mL/min/1.73 m2 (% of patients)
17.8
16.9
54.4
55.4
History of CVD (% of patients)
 
 
 
 
Coronary artery diseas
31.1
31.3
29.7
30.3
MI
17.4
16.8
13.3
13.7
Peripheral arterial occlusive disease
15.9
15.7
16.6
15.9
Ischemic stroke
12
11.6
11.6
12.7
Heart failure (% of patients)
7.9
7.7
6.9
8.5
Urinary albumin-to-creatinine ratio
 
 
 
 
Median (IQR) 
302 mg/g
315 mg/g
833 mg/g
867 mg/g
Glycated haemoglobin (%)
7.7±1.4
7.7±1.4
7.7±1.3
7.7±1.4
Systolic blood pressure (mmHg)
135.8±14.0
135.7±14.1
138.1±14.3
138.0±14.4
Select baseline medications (% of patients)
 
 
 
 
ACEi§
42.8
42.6
33.5
34.9
ARB§
57.2
57.4
66.3
65.0
Glucose-lowering therapies
97.9
97.9
97.0
97.7
Insulin
54.9
53.7
64.1
63.1
Metformin
69.5
68.4
44.2
43.6
GLP-1 receptor agonists
8.4
6.6
6.7
7.2
SGLT2 inhibitors
8.5
8.3
4.4
4.8
Statins
69.2
71.8
74.3
74.3
Antiplatelet agents
55.5
53.3
57.6
56.1
Alt tag
Alt tag

Firialta was studied in a wide variety of patients with CKD and T2D, across disease stages1

Alt tag

Select inclusion and exclusion criteria2,3

 
FIGARO-DKD
FIDELIO-DKD
Inclusion criteria
eGFR/
albuminuria
eGFR ≥60 mL/min/1.73 m2
with macroalbuminuria


OR

eGFR 25 to 90 mL/min/1.73 m2
with microalbuminuria
eGFR 25 to <60 mL/min/1.73 m2
with microalbuminuria
and diabetic retinopathy

OR

eGFR 25 to <75 mL/min/1.73 m2
with macroalbuminuria
Medications
Treated with standard-of-care background therapy, including maximum tolerated labelled dose of either an ACEi or an ARB
Serum
potassium
Serum potassium ≤4.8 mEq/L at screening
Exclusion criteria
Other
conditions
Symptomatic chronic HF with reduced ejection fraction
(New York Heart Association class II-IV)
Known significant non-diabetic kidney disease

Select inclusion and exclusion criteria2,3

Inclusion criteria

eGFR/albuminuria

FIGARO-DKD

eGFR ≥60 mL/min/1.73 m2 
with macroalbuminuria 

OR

eGFR 25 to 90 mL/min/1.73 m2
with microalbuminuria

FIDELIO-DKD

eGFR 25 to <60 mL/min/1.73 m2 
with microalbuminuria and 
diabetic retinopathy

OR

eGFR 25 to <75 mL/min/1.73 m2
with macroalbuminuria 

Medications

Treated with standard-of-care
background therapy, including
maximum tolerated labelled dose
of either an ACEi or an ARB

Serum potassium

Serum potassium ≤4.8 mEq/L
at screening

Exclusion criteria

Other conditions

Symptomatic chronic HF with
reduced ejection fraction 
(New York Heart Association class II-IV)

 

 

 

Known significant non-diabetic
kidney disease

Read about the clinical efficacy of Firialta
* 2.4% of patients had baseline eGFR <25 mL/min/1.73 m2 in the FIDELIO-DKD trial, and 0.4% in the FIGARO-DKD trial; 0.4% of patients had baseline UACR <30 mg/g in the FIDELIO-DKD trial, and 2.8% in the FIGARO-DKD trial.2,3
† Patients randomised.1-3
‡ If serum potassium was ≤4.8 mmol/L and eGFR was stable, patients were encouraged to increase their dose from 10 to 20 mg once daily. If serum potassium was >4.8 mmol/L and/or eGFR was not stable, patients could decrease their dose from 20 to 10 mg once daily.1
§ In the FIDELIO-DKD trial, 14 patients were not treated with either an ACEi or an ARB at baseline; 7 patients received treatment with both an ACEi and an ARB.3

 

ACEi=angiotensin-converting enzyme inhibitor; ARB=angiotensin receptor blocker; CKD=chronic kidney disease; CV=cardiovascular; CVD=cardiovascular disease; eGFR=estimated glomerular filtration rate; GFR=glomerular filtration rate; GLP-1=glucagon-like peptide 1; HF=heart failure; IQR=interquartile range; MI=myocardial infarction; SGLT2=sodium-glucose cotransporter 2; T2D=type 2 diabetes; UACR=urine albumin-to-creatinine ratio.

References:

  • Agarwal R, et al. Eur Heart J. 2022;43(6):474-484. doi:10.1093/eurheartj/ehab777. Return to content
  • Pitt B, et al. N Engl J Med. 2021;385(24):2252-2263. doi:10.1056/NEJMoa2110956. Return to content
  • Bakris GL, et al; FIDELIO-DKD Investigators. N Engl J Med. 2020;383(23):2219-2229. doi:10.1056/NEJMoa2025. Return to content
  • Ruilope LM, et al. Am J Nephrol. 2019;50(5):345-356. doi:10.1159/000503712. Return to content
  • Bakris GL, et al. Am J Nephrol. 2019;50(5):333-344. doi:10.1159/000503713. Return to content

© 2024 Bayer MY

This website was created by Bayer
and is intended to provide information to
healthcare professionals in Malaysia only.
PP-Fi-MY-0037-1 (10/24)